'The heart is back,' says Cardior CEO, as Novo's $1B deal boosts field
BioPharma
Source: biopharmadive.com
Thomas Thum News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Thomas Thum. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Thomas Thum Today - Breaking & Trending Today
Cardior Pharmaceuticals: Cardior Announces CE Marking of CardiorHealth miR-132 PCR Kit Used in Ongoing HF-REVERT Phase 2 Clinical Study
Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the CE marking of its PCR kit which
Source: finanznachrichten.de
New RNA therapies for the treatment of heart failure and organ fibrosis
RNA has already been making an impact in the context of the vaccine program, but the potential of RNA-based compounds is far from being fully tapped, as RNA allows for entirely new therapeutic approaches.
Source: news-medical.net
RNA Therapeutics 2022
SMi Group’s 13th Annual Conference:RNA Therapeutics 20229th – 10th February 2022London, UKwww.therapeutics-rna.com/pharmiweb Sponsored by: BIA Separations & eTheRNA ImmunotherapiesBolstering the latest advances and opportunities in RNA-based medicine The RNA therapeutics indust...
Source: pharmiweb.com
64 Millionen Euro zur Entwicklung RNA-basierter Therapien gegen Herzerkrankungen
Cardior Pharmaceuticals hat eine Serie-B-Finanzierung in Höhe von 64 Millionen Euro (USD 76 Millionen) abgeschlossen. Lead-Investor ist Inkef Capital, neue Co-Investoren sind Fund+, Sunstone, Hade ...
Source: bionity.com